Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002838566 | SCV003217730 | pathogenic | not provided | 2024-01-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln16Alafs*65) in the SCO2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 251 amino acid(s) of the SCO2 protein. This variant is present in population databases (no rsID available, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with SCO2-related conditions. This variant disrupts a region of the SCO2 protein in which other variant(s) (p.Gly193Ser) have been determined to be pathogenic (PMID: 19353847, 29193756, 32600061). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003475434 | SCV004202361 | likely pathogenic | Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1 | 2023-09-02 | criteria provided, single submitter | clinical testing |